Livestrong Cancer Institutes: A Decade of Collaboration
Impact Report 2024
Prepared by Dell Medical School and Livestrong Foundation
Overview
The Livestrong Cancer Institutes wer t bli h d i 2014 with a pledge of support from L Foundation to The University of Texa of the new Dell Medical School and the rigid cultures and outdated infras prevent transformation the institu advantage of a direct connection to T Texas at Austin and its vast, interdisc enterprise This combination of trans and clinical practice would allow for b lab to reach patients in the clinic at a
Established in 1997 with a mission to overlooked challenges in cancer care supported more than 10 million canc Notably, Livestrong played a pivotal r survivorship as a formal field of study space. Livestrong's empowering wor to encourage physical activity after c assistance for people whose treatme and a library of information available Along with individual care, Livestrong community programs that focus on t concerns of survivors and works with institutions to change how the world
The institutes opened our doors with comprehensive, patient-centered can care encompasses everything from d survivorship; where support services extend to families, loved ones and caregivers; where meeting the needs of underserved populations in Central Texas is essential, not an afterthought. From the beginning, Livestrong Cancer Institutes have operated with these goals as our north star:
Define, research and deliver patient-centered care throughout the cancer continuum. Improve the systems of cancer care delivery and the value for patients
Build local models of clinical and supportive care that could be exported and scaled to ensure access to high-quality care for everyone affected by cancer
Engage people affected by cancer in the design and deployment of care, education and research
In this report, we will examine the Livestrong Cancer Institutes’ progress both holistically and through the lenses of clinical care, research and education.
CARE
The Livestrong Cancer Institutes’ clinical practice began with a question: “can we reinvent the way cancer patients are cared for?” Minimizing cancer’s impact on patients, survivors and families was a core goal from the outset. We aimed to reinvent cancer care from the ground up with an integrated approach that addressed the needs of the whole person and their loved ones — not just their disease Care would be evidence-based and would reflect the latest discoveries, informed by research that our clinicians conduct in collaboration with leading scientists at The University of Texas at Austin.
Answering that question required evaluating the impact of holistic, whole-person care on health outcomes and post-care quality of life. It meant identifying cancer-related health needs throughout our community and finding solutions for them. It needed engagement and input from patients and survivors And it led us to develop and deliver novel, personcentered approaches for diagnostics, support services and treatment.
Disease Types Treated at Livestrong Cancer Institutes
Breast Cancer
Gynecologic Cancer
Hematologic Malignancies
Gastrointestinal Cancer
Surgical Oncology
Kristoffer Lands, cancer survivor
Clinical Practice
Since beginning clinical services in January 2019, our overall patient and visit volumes have grown, peaking at over 500 visits per month and averaging 310 visits per month (including medical, surgical and gynecological oncology visits). Across the same categories, new patient visits averaged 57 per month and peaked at over 100
Total Patient visits, Jan. 2019 – Present
Total Patient Visits – Medical Oncology
Total Patient Visits – Surgical Oncology
CLINICAL PRACTICE
Total
Patient Visits – Gynecological Oncology
Total New Patient Visits, Jan. 2019 – Present
MEDICAL ONCOLOGY
SURGICAL ONCOLOGY
GYNECOLOGICAL ONCOLOGY
A major success of the institutes has been the high levels of patient satisfaction Patients at every UT Health Austin clinic, including Livestrong Cancer Institutes, are given optional surveys to measure satisfaction, track outcomes, and identify areas for improvement Each patient is texted questions after the conclusion of an appointment, and responding is optional. Ninety-three percent of respondents rated Oncology positively, the highest evaluation of any UTHA clinic One contributor to that patient satisfaction is the CaLM model
CaLM Model
The Cancer Life reiMagined (CaLM) Model of Whole-Person Care was designed to deliver cuttingedge cancer therapies in coordination with psychosocial and palliative care This integrated approach attempts to address both the medical and personal needs of people with cancer and their families CaLM provides the most advanced treatment available in conjunction with support services for patients, families and caregivers
Oncologists and providers from other disciplines work in alignment to coordinate every aspect of the patient’s care, ensuring that the focus is not just on treating cancer but on creating a life well lived for the whole person. The model also integrates relaxation and stress-reduction strategies, nutritional guidance, financial planning, and emotional support, all of which make a tangible difference for patients and their families
Rachel, cancer survivor
The revolutionary approach was shaped by the Livestrong Foundation’s long-standing dedication to supporting people affected by cancer and by Dell Medical School’s emphasis on team-based care, which simplifies follow-ups and referrals
The CaLM model includes access to a panel of industry experts, informed by the latest research, to address each person ’ s unique needs Services provided include:
Diet and nutrition counseling
Onco-psychiatry
Clinical social work
Fertility preservation
Genetic counseling
Palliative care
With CaLM, patients don’t have to choose between getting well and living well they’d have both
Fertility Preservation
The fertility preservation program at UT Health Austin serves patients whose specific medical condition or treatment regimens may place them at risk for fertility complications in their future. The hope is to empower these patients to build their families the way they desire to in the future Fertility specialists educate the patient and families early on in their journey about the risks posed by their diagnosis and treatments, allowing them to determine if fertility preservation is viable and a good fit
LCI patients and their families are guided through all the options available to them, and the strengths, limitations, and science behind each one From there, we help them coordinate and complete fertility preservation in a timely manner so they can proceed with treatment We offer our patients many options, including GnRH therapy, egg and embryo freezing, ovarian tissue freezing and ovarian transposition for females, and sperm banking for males
How Comprehensive Care Changes Survivorship: Jason Dudey
Spring 2019 was off to a promising start for Baltimore native Jason Dudey Not only had he recently entered remission for non-Hodgkin lymphoma, but he was also moving to Austin to further his career in the live events industry, allowing him to work more closely with the city’s legendary music festivals.
To ensure Jason’s health remained stable throughout this transition, his doctor in Baltimore referred him to William Matsui, M.D., at Livestrong Cancer Institutes. Dr. Matsui specializes in treating nonHodgkin lymphoma and other cancers involving the blood, bone marrow, and/or lymph nodes.
During his initial visit, Jason was met with unwelcome news: his cancer had returned, meaning he would have to undergo treatment for stage four non-Hodgkin lymphoma in a new city, with a new care team. “No words can describe how it felt to learn my cancer had come back,” Jason said. “Within weeks of moving to Austin, I had resumed cancer treatment. Luckily, my experience was amazing.”
HOW COMPREHENSIVE CARE CHANGES SURVIVORSHIP: JASON DUDEY
Livestrong Cancer Institutes take multidisciplinary medicine seriously Patients benefit from the expertise of specialists across a variety of disciplines caring for them in one place to avoid scheduling numerous appointments with providers all over the city
“Having access to my entire care team during a single appointment made it easier to follow their recommendations,” Jason said. “Instead of juggling various appointments with different specialists while also undergoing chemotherapy, I was able to focus on my health.”
A few months into Jason’s chemotherapy treatment, Dr Matsui began the conversation around another option: bone marrow transplant. In this procedure, a donor’s healthy bone marrow cells are injected into a patient’s bloodstream and make their way into the patient’s bones, replacing the unhealthy bone marrow tissue that produces cancerous blood cells.
Following his successful transplant, Jason’s visits to the institutes have grown less frequent During each one, he found comfort in reconnecting with the care team who helped him through the most difficult moments of his cancer journey Perhaps the most unexpected obstacles he faced were the physical and mental challenges he experienced during his recovery
“I was never concerned about the medical aspects of my condition, because I had such a great team supporting me, ” Jason said “Still, I dealt with nonstop fatigue for almost a year after my transplant, making it hard to participate in work or social activities the way I used to ”
“I just wanted to be my old self again,” Jason said “Eventually, I realized I was trying for something that was unattainable ”
Jason’s care team at Livestrong Cancer Institutes prioritized his mental well-being throughout his journey.
“As a life-changing experience filled with uncertainty, cancer diagnosis and treatment can be psychologically traumatic for patients,” Dr. Matsui said.
“Having mental health support in place is critical to patient success.”
HOW COMPREHENSIVE CARE CHANGES
SURVIVORSHIP: JASON DUDEY
Jason’s care team included a UT Health Austin social worker, who put him in touch with two nonprofits that promote wellbeing within the local cancer community The first, the Flatwater Foundation, provides mental health services to individuals affected by cancer. Through this mental health support, Jason was able link his struggles to post-traumatic stress disorder (PTSD)
“My father was in the Army, and I grew up believing that PTSD only affected people who experienced military combat,” Jason shared “Acknowledging that I had also been impacted by trauma was an eye-opening experience ”
The second nonprofit, Regarding Cancer, partnered Jason with a peer survivor in the bone marrow transplant community who helped him understand what to expect during his recovery “Having experienced the transplant process himself, my peer survivor could empathize with me in a unique way, ” Jason said “No matter what I was going through, I had somebody by my side who understood my struggles.”
Four years later, Jason views his transplant as a new beginning, which he commemorated with a tattoo of his transplant date on his wrist “Spiritually, emotionally, and mentally, I’m a different person in a very positive way, ” Jason said “My cancer journey helped me realize what’s important and live according to those priorities ”
Livestrong at School EDUCATION
The future of cancer care depends on the next generation of oncology professionals — on recruiting smart, innovative and compassionate young people who accurately represent the broad range of people affected by cancer. Support from the Livestrong Foundation helped launch several Livestrong Cancer Institutes programs that have expanded opportunities and experiences for aspiring medical professionals, beginning as early as middle school and continuing through high school, college, medical school and beyond. These initiatives are identifying and encouraging students with the potential to change the lives of people with cancer.
Livestrong at School began as a partnership between the Livestrong Foundation and Scholastic to provide high school students with lesson plans to demystify cancer and empower students to make an impact through community engagement and cancer-related careers Beginning in 2018, LCI deployed the Livestrong at School curriculum to Austin-area schools and developed “Cancer Warriors” student panels to interact with physicians, researchers and cancer survivors and explore cancer-related careers. Between 2017 and 2023, 2,400 secondary students participated in the program.
The Summer Health Experience in Oncology The Summer Undergraduate Research Fellowship
The Summer Health Experience (SHE) in Oncology is a virtual, multi-institutional program for high school students who identify as female and are interested in science and medicine With the percentage of female active oncologists at around 28%, SHE aims to increase the number of women working in academia and oncology centers nationwide and is sponsored by the American Cancer Society
High school juniors and seniors attend lectures on the Dell Med campus and participate in hands-on research, clinical activities and leadership development. From 2019 to 2023, 59 high school students completed the program. During that time, we have expanded the experience to two weeks, increased the number of participants per cohort, and we plan a future national expansion to partner with cancer centers across the nation
Continuing our work requires up-and-coming researchers passionate about discovering the next breakthroughs in cancer prevention, diagnosis and treatment The Summer Undergraduate Research Fellowship (SURF) introduces the next generation of scientists to laboratory, translational and clinical research in oncology.
College undergraduates from across Texas and the U.S. have trained as SURF fellows and conducted independent research projects under the ip of Dell Med and UT Austin faculty attend lectures given by faculty and staff Dell Med, UT Austin and Texas Oncology
8-2023, 75 participants participated in the owship program and its successor, the Cancer Society Cancer Research
. The program is competitive: in 2024, nts applied for 20 spots in the 11-week with 15 slots reserved for students from
Hematology and Medical Oncology Fellowship
The comprehensive, three-year Hematology and Medical Oncology Fellowship is designed to develop leaders in clinical medicine and research who are dedicated to making high-quality, person-centered, multidisciplinary care the standard for cancer patients Under the direction of Boone Goodgame, M D , fellows train with Dell Med department of oncology faculty out of Livestrong Cancer Institutes
Cancer Uncovered
Since 2020, the institutes have produced a monthly podcast for learners of all ages interested in cancer and careers in health care “Cancer Uncovered: An Education and Empowerment Podcast” is a growing collection of interviews, talks and experiences that aims to empower and inspire Topics include healing the mind, body, and spirit of patients throughout cancer treatment and survivorship; health care disparities; nutrition in cancer care; and cancer and genetics.
Guided by world-class faculty mentors, our students and trainees are learning about the latest treatments of evidence-based cancer care and are undertaking meaningful research early in their careers in diverse fields of science and medicine They will go on to become leaders and innovators who will carry Dell Med’s vision to create a vital, inclusive health ecosystem across Texas, our nation, and the world.
Riding for Change: Rachel Boaz Gorham
The origin of medical student Rachel Boaz Gorham’s dedication to fighting cancer was unique among her class at Dell Medical School. In 2018, the then-neuroscience undergrad at UT Austin traveled by bicycle from Austin to Alaska on behalf of Texas 4000 for Cancer, an organization advancing cancer research and support services across the U.S. and Canada. Gorham led a team of her fellow riders as they biked more than 4,000 miles to Anchorage.
“Oncology is the reason I wanted to become a doctor; the people I met riding for Texas 4000 changed the way I view the world,” the Dell Med Class of 2023 graduate said.
“Complete strangers would see our jerseys and share stories of the loved ones they’d lost or their own fight with the disease.”
Rachel and her team raised and donated over $650,000 to cancer-fighting organizations, including Livestrong Cancer Institutes. “Now that I am part of the Dell Med family, it is such a privilege to witness the work being done here and know without a doubt that the cause I pedaled for is in the best possible hands.”
RIDING FOR CHANGE:
RACHEL BOAZ GORHAM
During four years as an undergrad, Rachel’s determination to improve cancer care only grew She spent that time equipping herself with the knowledge and skills needed to lead those efforts as a clinician. Studying and advancing patient experiences with the Livestrong Cancer Institutes’ clinical team, completing a Master of Science in Health Care Transformation, and leading Dell Med’s Cancer Interest Group provided countless lessons and informed the kind of physician she hopes to become
“While people like to believe that patients are at the center of health care, the reality is that their experiences are often overlooked, undervalued or simply unknown I want to turn the narrative and put the patient where they belong front and center, with a voice that’s not only listened to but proactively sought.”
Today, Rachel is an internal medicine resident at Vanderbilt University Medical Center in Nashville “I found ‘ my people’ on my IM rotations and cannot wait to begin the next part of my physician journey I am interested in following my residency with a fellowship in oncology, where I can use everything I’ve learned at Dell Med to improve the lives of cancer patients ”
I pursued medicine hoping to change it for the better. I intend to go into academic medicine and take on leadership roles to ensure the M.D.s who come after me understand what I’ve learned here at Dell Med: that health and care should be equitable, valuable and centered on the patient.
Rachel Boaz Gorham
RESEARCH
The Livestrong Foundation’s extraordinary vision, leadership and investment has enabled Livestrong Cancer Institutes to build a strong foundation of cancer research and discovery at Dell Medical School. We are driven by a deep desire to understand the causes of cancer through basic, translational and clinical research with a goal of revolutionizing patient-centered care Livestrong Foundation’s transformational gift during Dell Med’s infancy helped catalyze years of collaborative investigations across our campus and through external partnerships. The seed funding that launched the Institutes has created a ripple effect of impact, fueling phenomenal growth and inspiring further philanthropic support.
Risk-taking is the heart and soul of innovation, and our exceptional, creative scientists work tirelessly in their pursuit of groundbreaking research. They are leading the way in novel cancer therapies and diagnostics, using UT’s unrivaled research might in advanced computation, artificial intelligence, novel biologics and other emerging areas to redefine what a cancer diagnosis means for the people of Central Texas. Our faculty are blazing trails in many areas of cancer research with the potential to improve patient care and enhance quality of life both during and after treatment. Their discoveries could broadly impact lives here in Central Texas, our nation and around the world.
Discoveries that Spur New Ideas and Lead to Greater Understanding
As of July 2024, the Institutes, and Dell Med’s department of oncology, have received 44 grants and contracts totaling $13 5 million, evidence of the impact of the Foundation’s investment We continue to study the impact of the CaLM care model on cancer survivors and track the success of our patient education pilot, both critical to highlighting our shared belief that life after cancer is just as important as life with it.
Kim Foster, cancer survivor
Institutes number of joint research publications and grants by facilitating cross campus collaborations between bench scientists and clinicians, moving novel treatments from the laboratory to patients as quickly and safely as possible. The lab brings together physicians and researchers with diverse backgrounds and broad expertise in a comprehensive, integrated program dedicated to transforming care By collecting patient-derived tissues, the DTL is providing a crucial resource for discovery, one that informs clinical trials It is also a key training ground for earlycareer faculty as they develop their research interests and secure independent funding for future projects The lab is a major point of interest for prospective faculty members and helps attract top talent in cancer care and research to LCI and Dell Med
Computational Oncology for Personalized Care is an innovative partnership between Dell Med, UT’s Machine Learning Lab, and Oden Institute for Computational Engineering and Sciences, which uses computational oncology and machine learning to determine the most effective cancer treatments and personalized care plans for each individual patient LCI uses sophisticated mathematical models, imaging, and computer simulations to develop accurate predictions of how each patient will respond to treatment This technology is poised to enter the clinic, where we will test whether it can help determine the precise course of action for patients undergoing treatment for breast cancer
A leadership gift made in 2022 from Dheeraj and Swapna Pandey supports ongoing work that uses large data sets and novel computational tools to predict new therapies able to treat cancer cases resistant to standard drugs. Early results have identified novel molecular interactions that may lead to the use of drugs indicated for non-cancerous conditions to improve treatment efficacy. Other work seeks to advance our ability to model and predict cancer; imagines new computational tools to aid diagnosis and decision-making; and translates research into improved patient outcomes through personalized medicine
A Research Reputation that Attracts Additional Partners
LCI directs the American Cancer Society Institutional Research Grants for early-career faculty throughout UT, funding exceptional pilot projects that span all areas of cancer research, including laboratory, clinical, prevention/control, and psychosocial studies These pilot funds are pivotal in generating preliminary results that help investigators successfully compete for national research grants and foster direct relationships between UT Austin and the local ACS chapter.
In addition, LCI’s Cancer Prevention and Control Research Program serves as a home for scientists who aim to develop and implement comprehensive, evidence-based strategies that reduce the burden of cancer among disproportionally affected populations Program faculty have been awarded more than 50 grants and contracts totaling more than $30 million from funders including the National Institutes of Health, UT Austin’s Texas Biologics, MD Anderson and the American Cancer Society.
An Expanding Clinical Trials Program
The Clinical Trials Phase I Program advances the Institutes’ mission to improve treatment for people living with cancer by identifying and developing drugs that make cancer a livable disease The early-phase clinical trials program offers hope to people with cancer who have exhausted standard treatment options or when standard options don’t exist for their condition The program currently offers fifteen Phase 1 clinical trials (with 6 others pending approval) through collaborations with other UT Austin colleges and schools as well as Texas Oncology, the National Cancer Institute at the National Institutes of Health, MD Anderson Cancer Center and other partners
These clinical trials include studies of treatments, diagnostics and progression of:
Endometrial serous carcinoma or carcinosarcoma (HER2+, Stage I-IV)
Pancreatic ductal adenocarcinoma
Relapsed and/or refractory myeloma
Relapsed or refractory aggressive B-cell Non-Hodgkin’s lymphoma
RAS mutations in non-small cell lung cancer, Pancreatic ductal adenocarcinoma, colorectal cancer, melanoma, and other solid tumor cancers
HER2+ expressions in colorectal or gastroesophageal cancer
Livestrong Cancer Institutes operate from a vision of hope and healing in a world where cancer patients can survive, thrive and live their best lives. The values instilled in LCI are spreading exponentially, reaching more communities and inspiring generations of future physicians, patients and survivors. Because of the support and example of Livestrong Foundation, we look confidently to the future, knowing we have left an enduring imprint on our community.
DR. WILLIAM MATSUI, M.D.
Livestrong Foundation commits $50 million to help create and support the Livestrong Cancer Institutes at Dell Medical School
Dell Medical School lays the groundwork for a cancer clinic, strategically recruiting physicians, researchers and staff
LCI officially launches with the arrival of Inaugural Director, S Gail Eckhardt, M D
LCI opens the Developmental Therapeutics Lab for cancer research and establishes multiple research collaborations across UT Austin with College of Natural Sciences, Cockrell School of Engineering, College of Liberal Arts, Steve Hicks School of Social Work, School of Nursing, College of Pharmacy
Cancer center expands work in research collaborations, administration and education
LCI releases first strategic plan
Summer Undergraduate Research Fellowship (SURF) welcomes its first fellows
Livestrong at School Program begins
LCI clinic opens and accepts first patients, with a focus on gastrointestinal cancers
Tumor boards begin
LCI begins offering onco-fertility services
Summer Health Experience in Oncology (SHE) program launches
LCI wins Association of Community Cancer Centers’ Innovator Award for the CaLM Model of Cancer Care
LCI finalizes clinical trials capabilities partnership with Ascension Seton and opens first study
LCI clinical research program begins
SHE program welcomes its first national cohort, working with five universities
Young Adult Cancer Program begins
First two hematology and medical oncology fellows begin
SHE program begins a second cohort of five universities
Research effort merges computational oncology and machine learning through partnership between Dell Med, Machine Learning Lab and Oden Institute for Computational Engineering and Sciences, established with gift from Dheeraj and Swapna Pandey
Meet the Team
The Livestrong Foundation’s initial investment in Livestrong Cancer Institutes brought together exceptional physicians and researchers who are driven to better understand the causes of cancer and help our patients live beyond diagnosis and treatment. The depth and breadth of their talent is unsurpassed.
In addition to the following six regular faculty at the LCI, there are also 36 courtesy faculty members and nine affiliate faculty members.
Kyaw Aung, M.D., Ph.D.
Assistant Professor, Department of Oncology, Dell Medical School
Dr Kyaw Aung is a medical oncologist and physician scientist who specializes in treating patients with gastrointestinal cancers He is part of both UT Health Austin’s Hereditary Cancer Screening and Risk Reduction care team and CaLM Care Team His laboratory research focuses on understanding pancreatic cancer biology to develop new personalized treatment strategies for patients with pancreatic cancer. He earned his medical degree from the University of Medicine 1, Yangon in Myanmar and his doctorate from The University of Manchester in the United Kingdom He then completed a residency in internal medicine at Lincoln County Hospital in the United Kingdom; a fellowship in medical oncology at Clatterbridge Cancer Center in Liverpool; and a second fellowship in early phase oncology drug development and gastrointestinal cancers at Princess Margaret Cancer Center/the University of Toronto in Canada before coming to Dell Med in December 2018.
Boone Goodgame, M.D.
Associate Professor, Department of Oncology, Dell Medical School
Courtesy Associate Professor, Department of Internal Medicine, Dell Medical School
Medical Director for Oncology for Ascension Seton Program Director, Hematology & Medical Oncology Fellowship, Dell Medical School
Dr Boone Goodgame is the medical director for oncology for Ascension Seton who came to Austin in 2010 to be part of the development of the new Dell Medical School He leads the clinical hematology and oncology teaching faculty at Dell Med and Dell Seton Medical Center and chairs the Ascension Seton Cancer Committee He cares for patients and conducts research in all areas of hematology and oncology but has a particular interest in treatment and clinical research in lung cancer and genitourinary cancers After earning a medical degree from Baylor College of Medicine and completing his residency and fellowship at Barnes Jewish Hospital and Washington University School of Medicine in St. Louis, he joined the faculty at Washington University, focusing on translational research in lung and genitourinary cancers (kidney, bladder and prostate)
William Matsui,
M.D.
Vice Dean of Research, Dell Medical School
Professor, Department of Oncology, Dell Medical School
Courtesy Professor, Department of Internal Medicine, Dell Medical School
Dr William Matsui is an oncologist who specializes in caring for patients with cancers that involve the blood and bone marrow, as well as bone marrow transplantation He has carried out laboratory-based translational research focused on cancer stem cells, tumor cells with enhanced growth potential and their role in clinical oncology The Matsui lab has emphasized translational research and successfully built on its findings to carry out clinical trials testing innovative therapies In 2018, he came to Dell Med from Johns Hopkins University School of Medicine, where he directed the Multiple Myeloma Program and co-directed the Division of Hematologic Malignancies He earned his medical degree from the University of California at San Francisco, completed residency training in internal medicine at the University of Washington in Seattle, and completed his clinical training in medical oncology at Johns Hopkins
Jeanne Kowalski-Muegge, Ph.D.
Associate Director of Cancer Clinical Genomics, Livestrong Cancer Institutes, Dell Medical School
Co-Program Leader of Quantitative Oncology, Livestrong Cancer Institutes, Dell Medical School
Professor, Department of Oncology, Dell Medical School
Dr Jeanne Kowalski-Muegge is a leader in cancer biostatistics and bioinformatics At Dell Med, she oversees the clinical sequencing of patient tumors and leads a research molecular tumor board to critically evaluate how molecular tumor profiles could be cross-examined in cancer public domain data She is building analysis workflows to improve the information exchange between tumor molecular profiles and drug compounds with clinical outcomes She came to Dell Med in January 2019 from Winship Cancer Institute at Emory University, where she was the founding director leading the blended discipline core, biostatistics and bioinformatics to support cancer research. After completing a doctoral degree at the University of Pittsburgh and a fellowship at Harvard School of Public Health, she became an integral faculty member of the cancer biostatistics core to support cancer research at Johns Hopkins University School of Medicine.
Om Pandey, M.D.
Associate Professor, Department of Oncology
Courtesy Associate Professor, Department of Internal Medicine
Associate Program Director, Hematology & Medical Oncology Fellowship
Om N. Pandey, MD is a board-certified medical oncologist and hematologist in Austin, TX He moved to Austin from Minneapolis in 2008. He has been actively involved in medical education and clinical research at Dell Medical School at UT Austin and has won awards for excellence in teaching
Debra Patt, M.D., MPH
Professor, Department of Oncology, Dell Medical School Executive Vice President, Texas Oncology
Dr Debra Patt is a practicing oncologist, breast cancer specialist and leader in breast cancer and research in healthcare informatics driving digital healthcare tool adoption in clinical practice to improve the patient experience She is the Medical Director for Public Policy for The U S Oncology Network and has testified before the U.S. Congress and Senate to protect access to care for cancer patients She earned her medical degree and completed a residency in internal medicine and pediatrics at Baylor College of Medicine; completed the Cancer Prevention Program at National Cancer Institute; earned a Master of Public Health with a focus on cancer health and policy and Ph D in health economics and health services research from UTHealth Houston School of Public Health; completed a fellowship in hematology and medical oncology at MD Anderson Cancer Center; and earned a master of business administration from The University of Texas at Austin
Impact Report 2024
Prepared by Dell Medical School and Livestrong Foundation For more information, please contact: contact info